Trials / Conditions / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11

Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11

20 registered clinical trials studyying Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11.

Status	Trial	Sponsor	Phase
Completed	Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01664897	M.D. Anderson Cancer Center	Phase 2
Completed	Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia NCT01870596	National Cancer Institute (NCI)	Phase 2
Completed	Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia NCT01361464	National Cancer Institute (NCI)	Phase 2
Completed	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemother NCT01307579	Children's Oncology Group	Phase 3
Completed	Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01238211	National Cancer Institute (NCI)	Phase 2
Terminated	Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute My NCT01260714	National Cancer Institute (NCI)	Phase 1
Completed	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578	National Cancer Institute (NCI)	Phase 1
Completed	Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacit NCT01168219	National Cancer Institute (NCI)	Phase 2
Completed	Veliparib and Temozolomide in Treating Patients With Acute Leukemia NCT01139970	National Cancer Institute (NCI)	Phase 1
Completed	Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT01132586	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leuke NCT00658814	National Cancer Institute (NCI)	Phase 2
Completed	Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu NCT00588991	National Cancer Institute (NCI)	Phase 1
Completed	Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute NCT00416598	National Cancer Institute (NCI)	Phase 2
Completed	Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Ph NCT00383474	National Cancer Institute (NCI)	Phase 1
Completed	Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586	National Cancer Institute (NCI)	Phase 2
Completed	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975	National Cancer Institute (NCI)	Phase 1
Completed	Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blast NCT00217646	National Cancer Institute (NCI)	Phase 1
Completed	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001	Fred Hutchinson Cancer Center	Phase 2
Completed	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission NCT00093470	National Cancer Institute (NCI)	Phase 3
Completed	Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia NCT01005277	Children's Oncology Group	—